Open Label Extension to Bridging Study CTBM100C2303

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 21, 2009
Last updated: May 2, 2012
Last verified: May 2012

This is an open-label, single arm (uncontrolled) study in subjects suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.

Condition Intervention Phase
Pseudomonas Aeruginosa
Cystic Fibrosis
Drug: Tobramycin inhalation powder
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Safety of tobramycin inhalation powder for the treatment of infections with P. aeruginosa in subjects suffering from cystic fibrosis. [ Time Frame: Each visit during the 168-day treatment period ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Efficacy of tobramycin inhalation powder, assessed by spirometry [ Time Frame: Each visit during the 168-day treatment period ] [ Designated as safety issue: No ]
  • Density of microorganisms in sputum samples [ Time Frame: Each visit (except last visit) during the 168-day treatment period ] [ Designated as safety issue: No ]

Enrollment: 57
Study Start Date: August 2009
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TIPnew Drug: Tobramycin inhalation powder
Tobramycin inhaled powder


Ages Eligible for Study:   6 Years to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed all visits in study CTBM100C2303, and visit 4 took place not more than 5 days before enrollment into this study.
  • Confirmed diagnosis of cystic fibrosis patients with P. aeruginosa infection.
  • FEV1 at screening (study CTBM100C2303) must be between 25% and 80% of normal predicted values.

Exclusion Criteria:

  • Any use of inhaled anti-pseudomonal antibiotics between the termination of the core trial CTMB100C2303 and the enrollment into this study.
  • Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00982930

Novartis Investigative Site
Tallin, Estonia
Russian Federation
Novartis Investigative Site
Yaroslavl, Russian Federation
Sponsors and Collaborators
Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT00982930     History of Changes
Other Study ID Numbers: CTBM100C2303E1, EudraCT 2008-004764-39
Study First Received: September 21, 2009
Last Updated: May 2, 2012
Health Authority: Estonia: The State Agency of Medicine
Russia: Ministry of Health of the Russian Federation
United States: Food and Drug Administration

Keywords provided by Novartis:
Tobramycin Inhalation Powder
Cystic fibrosis
Lung diseases
Anti-Bacterial Agents

Additional relevant MeSH terms:
Cystic Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses processed this record on October 21, 2014